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Introduction
Intravascular continuous glucose monitoring (CGM) in
critically ill patients represents a major advance to
improve the quality of care and to decrease the nursing
workload dedicated to glycemic control. However, the
presence of several physical or chemical interferences
can limit the accuracy of the blood glucose readings
(BG) measured by the CGM, implying the need for a
thorough validation process for each technique or device
used for CGM.
Objectives
To assess the accuracy of Optiscanner (Optiscan Corp,
Hayward, CA), which directly measures mid infrared
absorption of glucose in plasma.
Methods
Adult medical and surgical critically ill patients with an
expected length of stay in the ICU of at least 3 days, an
admission BG > 150 mg/dl and a need for central venous
and arterial catheterization were enrolled after signed
informed consent. A 4-lumen central venous catheter
was inserted into the superior vena cava and the proxi-
mal port was connected to the OptiScanner. Blood was
drawn every 15 minutes and BG was determined on
0.1 mL of centrifuged blood by mid-infrared spectro-
scopy. Comparative samples were drawn 12 times per
day separated by a minimum 60-min time interval. BG
reference values were measured by two different blood
gas analysers (YSI 2300 STAT Plus and GEM4000). BG
measured with the Optiscanner were plotted against the
reference BG on a Clarke error grid (CEG). The percen-
tage of values in the A and B zones of the CEG, i.e when
BG values were within 20% of the reference sensor, or
when the inaccuracy would not influence the treatment,
and the mean amplitude of the relative difference
(MARD) were determined.
Results
Eighty-five patients (median age 63 years (range 21-88),
predominantly males (65%) with a median APACHE II
score of 20 (range 6-41) were included. The ICU and hos-
pital mortality were 19 and 20 %, respectively. 8,430 BG
values were determined by the OptiScanner and 862
paired BG, ranging from 60 to 352 mg/dl, values were ana-
lysed. The percentage of values between 70 and 150 mg/dl
were 60% and 58.6% when measured by the OptiScanner
and the blood gas analyzers, respectively. The percentage
of values in the A and B zones of the CEG were 95.1 and
4.8% The MARD was 8%.
Conclusions
The Optiscanner provided reliable and accurate BG values
over a large range of values in a heterogeneous population
of ICU patients. The impact of a therapeutic strategy
using this device on glucose control performance and
indices of nursing workload should be studied.
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